Laser zap before eye injection could cut needle count for wet AMD

NCT ID NCT07744204

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study tests whether a low-intensity laser applied to the diseased area just before an anti-VEGF injection helps the drug work better in people with wet age-related macular degeneration (AMD). Wet AMD causes abnormal blood vessels to leak fluid under the retina, and current treatment requires frequent eye injections. The trial will compare patients who receive laser plus injection versus injection alone, tracking how many injections are needed over 24 months. If the laser enhances drug delivery, patients may need fewer injections, reducing the burden of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Laser photocoagulation (577-nm yellow laser) combined with anti-VEGF injections (conbercept, aflibercept, ranibizumab, or faricimab)
What this could lead to
If successful, this approach could reduce the number of eye injections needed for wet AMD, easing the treatment burden for patients.
What could go wrong
The trial is relatively small and early, and the laser may not enhance drug delivery as hoped. There are also risks of laser-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.